NIOX Group (LON:NIOX) Announces Quarterly Earnings Results

NIOX Group (LON:NIOX) released its quarterly earnings results on Tuesday. The company reported GBX 4.03 earnings per share for the quarter, Digital Look Earnings reports. NIOX Group had a return on equity of 8.39% and a net margin of 11.30%.

NIOX Group Price Performance

NIOX Group stock traded up GBX 3.40 during trading hours on Tuesday, reaching GBX 57.80. 3,000,305 shares of the stock were exchanged, compared to its average volume of 813,313. The company has a current ratio of 3.73, a quick ratio of 1.94 and a debt-to-equity ratio of 1.86. NIOX Group has a twelve month low of GBX 53.40 and a twelve month high of GBX 77.60. The company has a market cap of £241.57 million, a P/E ratio of 46.24 and a beta of 0.92. The stock has a 50 day moving average of GBX 64.53 and a two-hundred day moving average of GBX 68.35.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft decreased their price objective on NIOX Group from GBX 90 to GBX 86 and set a “buy” rating on the stock in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of GBX 88.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.